目的 探讨血清微RNA(microRNA,miRNA)液体活检在早期卵巢癌诊断中的临床价值。方法 选取2021—2023年湖州市妇幼保健院的22个新鲜冷冻Ⅰ期卵巢癌组织和9个相邻正常卵巢组织用于本研究。使用R软件中的limma软件包分析肿瘤和邻近正常组织...目的 探讨血清微RNA(microRNA,miRNA)液体活检在早期卵巢癌诊断中的临床价值。方法 选取2021—2023年湖州市妇幼保健院的22个新鲜冷冻Ⅰ期卵巢癌组织和9个相邻正常卵巢组织用于本研究。使用R软件中的limma软件包分析肿瘤和邻近正常组织之间miRNA的差异表达。利用公开的回顾性血清miRNA测序数据集GSE106817使用Ⅰ期卵巢癌中高表达的miRNA训练Logistic回归模型,使用GSE113486和GSE31568验证模型的准确性。结果 Ⅰ期卵巢癌组织中共筛选出8种高表达miRNA,即miR-182、miR-183、miR-202、miR-205、miR-508、miR-509-3、miR-513B和miR-513C。在训练队列GSE106817中用于诊断卵巢癌的曲线下面积(area under the curve,AUC)为0.89。在验证队列GSE31568和GSE113486中诊断卵巢癌的AUC分别为0.85和0.86。结论 血清miRNA液体活检对早期卵巢癌的诊断有较高的临床价值。展开更多
液体活检技术在妇科恶性肿瘤中的应用研究取得了显著进展,为临床诊断和治疗带来了新的希望。作为一种无创性检测方法,液体活检通过分析血液中的循环肿瘤细胞(CTCs)、循环肿瘤DNA (ctDNA)及外泌体等生物标志物,实现了对肿瘤的早期诊断、...液体活检技术在妇科恶性肿瘤中的应用研究取得了显著进展,为临床诊断和治疗带来了新的希望。作为一种无创性检测方法,液体活检通过分析血液中的循环肿瘤细胞(CTCs)、循环肿瘤DNA (ctDNA)及外泌体等生物标志物,实现了对肿瘤的早期诊断、治疗监测和预后评估。其非侵入性和动态监测能力使其在克服传统组织活检局限性方面展现出独特优势。液体活检不仅能够为妇科恶性肿瘤的早期诊断做出贡献,还能在治疗过程中实时追踪肿瘤变化,指导个体化治疗策略的制定。然而,液体活检技术在临床应用中仍面临灵敏度、特异性、标准化等挑战。未来,随着技术的不断完善和研究的深入,液体活检有望在妇科恶性肿瘤的管理中发挥更为重要的作用,为患者提供更为精准和个性化的医疗服务。The application of liquid biopsy technique in gynecological malignant tumor has made remarkable progress, which brings new hope for clinical diagnosis and treatment. As a noninvasive test, liquid biopsy achieves early diagnosis, treatment monitoring, and prognostic evaluation of tumors by analyzing biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes in the blood. Its non-invasive and dynamic monitoring capabilities give it unique advantages in overcoming the limitations of traditional tissue biopsy. Liquid biopsy can not only contribute to the early diagnosis of gynecological malignancies, but also track tumor changes in real time during treatment and guide the development of individualized treatment strategies. However, liquid biopsy techniques still face challenges such as sensitivity, specificity, and standardization in clinical applications. In the future, with the continuous improvement of technology and the deepening of research, liquid biopsy is expected to play a more important role in the management of gynecological malignancies and provide more accurate and personalized medical services for patients.展开更多
文摘目的 探讨血清微RNA(microRNA,miRNA)液体活检在早期卵巢癌诊断中的临床价值。方法 选取2021—2023年湖州市妇幼保健院的22个新鲜冷冻Ⅰ期卵巢癌组织和9个相邻正常卵巢组织用于本研究。使用R软件中的limma软件包分析肿瘤和邻近正常组织之间miRNA的差异表达。利用公开的回顾性血清miRNA测序数据集GSE106817使用Ⅰ期卵巢癌中高表达的miRNA训练Logistic回归模型,使用GSE113486和GSE31568验证模型的准确性。结果 Ⅰ期卵巢癌组织中共筛选出8种高表达miRNA,即miR-182、miR-183、miR-202、miR-205、miR-508、miR-509-3、miR-513B和miR-513C。在训练队列GSE106817中用于诊断卵巢癌的曲线下面积(area under the curve,AUC)为0.89。在验证队列GSE31568和GSE113486中诊断卵巢癌的AUC分别为0.85和0.86。结论 血清miRNA液体活检对早期卵巢癌的诊断有较高的临床价值。
文摘液体活检技术在妇科恶性肿瘤中的应用研究取得了显著进展,为临床诊断和治疗带来了新的希望。作为一种无创性检测方法,液体活检通过分析血液中的循环肿瘤细胞(CTCs)、循环肿瘤DNA (ctDNA)及外泌体等生物标志物,实现了对肿瘤的早期诊断、治疗监测和预后评估。其非侵入性和动态监测能力使其在克服传统组织活检局限性方面展现出独特优势。液体活检不仅能够为妇科恶性肿瘤的早期诊断做出贡献,还能在治疗过程中实时追踪肿瘤变化,指导个体化治疗策略的制定。然而,液体活检技术在临床应用中仍面临灵敏度、特异性、标准化等挑战。未来,随着技术的不断完善和研究的深入,液体活检有望在妇科恶性肿瘤的管理中发挥更为重要的作用,为患者提供更为精准和个性化的医疗服务。The application of liquid biopsy technique in gynecological malignant tumor has made remarkable progress, which brings new hope for clinical diagnosis and treatment. As a noninvasive test, liquid biopsy achieves early diagnosis, treatment monitoring, and prognostic evaluation of tumors by analyzing biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes in the blood. Its non-invasive and dynamic monitoring capabilities give it unique advantages in overcoming the limitations of traditional tissue biopsy. Liquid biopsy can not only contribute to the early diagnosis of gynecological malignancies, but also track tumor changes in real time during treatment and guide the development of individualized treatment strategies. However, liquid biopsy techniques still face challenges such as sensitivity, specificity, and standardization in clinical applications. In the future, with the continuous improvement of technology and the deepening of research, liquid biopsy is expected to play a more important role in the management of gynecological malignancies and provide more accurate and personalized medical services for patients.
